Revelation Biosciences (REVB) stock ticks up premarket after FDA lays out Gemini trial path
Revelation Biosciences shares climbed roughly 2% in premarket Friday, adding to a rollercoaster week for the lightly traded biotech. Investors were reacting to the company’s newest regulatory update. The stock last changed hands near $0.85.